semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-74.0,  Breast Cancer for Breast Cancer and High-Risk Patients Age greater than or equal to 18 years and less than or equal to 74 years Women with a unilateral invasive or noninvasive (DCIS) breast cancer of epithelial origin Women without breast cancer, but with a Gail Index greater than 1.67 percent, or a cumulative lifetime risk greater than or equal to double the age and race-matched general population risk Women known to be BRCA1/2 or other hereditary genes mutation carriers Women with cytologic or histologic evidence of ductal hyperplasia, atypical ductal hyperplasia, or LCISl Women may be either premenopausal or postmenopausal. Postmenopausal is defined by the absence of menstrual periods for at least 12 months Postmenopausal women who have previously undergone a hysterectomy without oophorectomy must have a serum FSH level of greater than 40 IU/ml, and a serum estradiol level of less than 40 pg/ml to document postmenopausal status Breast cancer may be invasive or noninvasive, and in the past or the present  for Breast Cancer Patients Contralateral breast prosthesis Pregnancy History of radiation therapy to the contralateral breast Lactating breasts Chemotherapy within the past 1 month Current antiestrogen therapy Current hormonal replacement therapy or oral contraceptives Concurrent infection Previous contralateral major duct excision
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Vestibular Neuronitis Vestibulopathy Main vestibulopathy and locomotor unsteadiness Main  diseases/impairments that prevent rehab participation
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Histologically confirmed ductal carcinoma in situ (DCIS) of the breast Mixed DCIS and lobular carcinoma in situ (LCIS) allowed Must have undergone lumpectomy Margins must be histologically free of disease Re-excision to obtain tumor-free margins allowed No more than 84 days since prior lumpectomy or re-excision More than 1 area of DCIS allowed provided all disease is removed with tumor-free margins Masses or clusters of calcification that are clinically or mammographically suspicious must be biopsied No prior invasive breast cancer or DCIS Patients with a history of LCIS are eligible
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-120.0,  Breast Cancer Histologically confirmed ductal carcinoma in situ or invasive adenocarcinoma of the breast Primary tumor classified as T1, T2, or T3 Candidate for breast-conserving surgery Must have undergone lumpectomy with negative margins or minimal margin involvement Currently undergoing re-excision of the biopsy cavity and/or sentinel lymph node biopsy or axillary lymph node dissection No evidence of metastatic disease Hormone receptor status Not specified Age Adult Sex Female Menopausal status
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-120.0,  Breast Cancer Histologically confirmed invasive breast cancer pT1-3; pNX, pN0-2 or pN3*; M0 Neoadjuvant patients are eligible no earlier than 3 weeks or later than 3 months after excisional surgery, provided both the clinical-diagnostic staging of cancer and postsurgical resection-pathologic staging of cancer meet the requirements for primary tumor, regional lymph nodes, and distant metastasis classification NOTE: *Only when the sole basis for this classification is the presence of 10 or more involved axillary lymph nodes Completely resected disease Primary surgery performed at least 3 weeks but no more than 3 months before study entry (if no chemotherapy was given) Primary surgery is defined as the last surgery at which histologic evidence of invasive or in situ disease was present in the pathology specimen Patients with positive sentinel lymph node biopsy are eligible provided they have had a subsequent axillary lymph node dissection No metachronous breast cancer Bilateral mammogram within the past 12 months unless initial surgery was a total mastectomy, in which case only a mammogram of the remaining breast is required No metastases confirmed by 1 of the following methods
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed invasive breast cancer Stage I or II (T1, N0; T1, N1; T2, N0; or T2, N1) Unifocal disease (single focus that can be encompassed by one lumpectomy) The following histologies are eligible Invasive ductal Medullary Papillary Colloid (mucinous) Tubular No invasive or extensive in situ lobular carcinoma or pure ductal carcinoma in situ (DCIS)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Cervical Squamous Cell Carcinoma Stage I Cervical Cancer Diagnosis of carcinoma of the cervix of 1 of the following cellular types Squamous cell carcinoma Adenocarcinoma Adenosquamous cell carcinoma Stage IB1 disease (no greater than 4 cm) No unequivocal evidence of metastases Adequate surgical candidate No known allergy to triphenylmethane compounds No prior pelvic irradiation No prior retroperitoneal surgery
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and unifocal breast carcinoma Largest tumor lesion ≤ 5 cm Palpable or nonpalpable breast lesion Preoperative radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions Prior (preoperative) or planned (intraoperative) sentinel node biopsy required At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension No clinical evidence of distant metastases No suspicious manifestation of metastases that cannot be ruled out by x-ray, MRI, or CT scan, including the following Skeletal pain of unknown cause Elevated alkaline phosphatase
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 35.0-999.0,  Breast Cancer Histologically confirmed ductal carcinoma in situ (DCIS) of the breast OR mammogram highly suspicious for DCIS No invasive disease Not completely excised Epidermal growth factor receptor (EGFR) positive (> 10% of cells stained) Planned lumpectomy or mastectomy within the next 2-4 weeks Hormone receptor status Estrogen receptor status known Age and over Sex Female Menopausal status Not specified Performance status
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Patients must be greater than or equal to 18 years of age The patient must have a life expectancy of at least 10 years, excluding her diagnosis of breast cancer. (Comorbid conditions and performance status should be taken into consideration, but not the diagnosis of breast cancer.) The interval between the last surgery for breast cancer treatment (lumpectomy, mastectomy, sentinel lymph node biopsy, axillary surgery, or re-excision of lumpectomy margins) and randomization must be no more than 84 days The tumor must be invasive adenocarcinoma on histologic examination. (Patients with tumors that are pure tubular or mucinous adenocarcinomas are not eligible.) The primary tumor must be T1-3 by clinical and pathologic evaluation Lymph nodes obtained from all axillary staging procedures must be pN0 according to pathologic staging of the 6th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Patients must have undergone axillary nodal staging procedures, for example sentinel node (SN) biopsy alone, SN biopsy followed by axillary sampling or completion dissection, or axillary node dissection to obtain lymph nodes for pathologic evaluation. If the patient has palpable nodes, axillary dissection is required Patients must have an estrogen receptor (ER) analysis performed on the primary tumor prior to randomization. If ER is negative, then progesterone receptor (PgR) analysis must be performed. If ER is positive, PgR analysis is desired, but not mandatory. ("Marginal" or "borderline" results [i.e., those not definitively negative] will be considered positive regardless of the methodology used.) Patients must have had either a lumpectomy or total mastectomy Patients must have no clinical or radiologic evidence of metastatic disease
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed infiltrating carcinoma of the breast Unresected disease High-risk (> 50% risk of relapse) disease, including any of the following high-risk markers Estrogen receptor and progesterone receptor negative Palpable axillary lymph nodes Grade 3 histology S phase fraction > 10% Ki67 > 30%
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed ductal carcinoma in situ (DCIS*) or invasive* adenocarcinoma of the breast Stage 0, I, or II disease Stage II tumors must be ≤ 3 cm Gross disease must be unifocal Microscopic multifocality allowed provided total pathological tumor size is ≤ 3 cm No proven multicentric carcinoma in more than 1 quadrant or separated by ≥ 4 cm No non-epithelial breast malignancies (e.g., sarcoma or lymphoma) NOTE: *Patients who are 50 years of age and over with DCIS regardless of hormone receptor status AND patients with invasive breast cancer meeting all of the following ≥ 50 years of age, node-negative, and hormone-receptor positive status will not be enrolled in study after 12/30/2006 Prior axillary staging required for patients with invasive breast cancer, including 1 of the following Sentinel node biopsy alone (if sentinel node is negative) Sentinel node biopsy followed by axillary dissection or sampling with ≥ 6 axillary nodes (if sentinel node is positive)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed ductal carcinoma in situ (DCIS) of the breast OR DCIS with microinvasion (< 1 mm) by core biopsy or excisional biopsy HER2/neu positive tumor, defined as > 10% of the tumor population expressing HER2/neu by immunohistochemical staining No evidence of invasive disease by MRI (performed within the past month) Hormone receptor status Not specified Age Over 18 Sex Not specified Menopausal status Not specified Performance status ECOG 0-1 Life expectancy Not specified Hematopoietic
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Neoplasms Written informed consent Operable breast cancer patients (T1-T3) with negative axillary lymph nodes (10 axillary nodes dissection) and high risk according to St. Gallen consensus criteria Histologically proven breast cancer. Interval between surgery and registration is less than 60 days Definitive surgical treatment must be either mastectomy, or breast conservative surgery. Margins of resected specimen from surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma in-situ (DCIS). Lobular carcinoma in-situ is not considered as positive margin Patients without proven metastatic disease Estrogen and progesterone receptors performed on the primary tumour prior to randomization Age between 18 years and 70 years Karnofsky performance status index > 80 % Adequate hepatic, renal and heart functions Adequate hematology levels  Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy) Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy Prior radiation therapy for breast cancer Bilateral invasive breast cancer Pregnant, or lactating patients Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment  Any T4 or N1-3 or M1 breast cancer Pre-existing motor or sensory neurotoxicity of a severity grade 2 by NCI criteria Other serious illness or medical condition Past or current history of neoplasm other than breast carcinoma
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Histologically confirmed ductal carcinoma in situ (DCIS) of the breast T0 disease Newly diagnosed disease by minimally invasive biopsy (e.g., a vacuum-assisted large core tool [mammotome] or an equivalent method) Biopsy tissue available for molecular marker analysis Baseline mammography performed within the past 8 weeks Hormone receptor status Not specified Age Postmenopausal Sex Female Menopausal status Postmenopausal, as defined by 1 of the following